Clusterin confers gmcitabine resistance in pancreatic cancer

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Chen, Qingfeng ^a   Wang, Zhengkun ^a   Zhang, Kejun ^a   Liu, Xiaoyi ^a   Cao, Weihong ^a   Zhang, Lei ^a   Zhang, Shuhua ^a   Yan, Bomin ^a   Wang, Yaoguang ^b,c   Xia, Chunping ^b,c  

^a QINGDAO UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CLUSTERIN; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CHEMOSENSITIVITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CLUSTERIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956271360     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-59     Document Type: Article

References (27)

1. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, Schäfer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gmcitabine-induced cell death. Oncogene 2003, 22:3243-51. 10.1038/sj.onc.1206390, 12761494.
2. Rosenberg ME, Silkensen J. Clusterin: Physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995, 27:633-645. 10.1016/1357-2725(95)00027-M, 7648419.
3. Kyprianou N, English HF, Davison NE, Issac JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 1991, 51:162-166.
4. Wright PS, Cross-Doersen D, Th'ng JP, Guo XW, Crissman HA, Bradbury EM, Montgomery LR, et al. A ribonucleotide reductase inhibitor, MDL 101, 731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp Cell Res 1996, 222:54-60. 10.1006/excr.1996.0007, 8549673.
5. Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggressive and nonaggressive properties. Kidney Int 1998, 53:1647-1653. 10.1046/j.1523-1755.1998.00902.x, 9607196.
6. Savković V, Gantzer H, Reiser U, et al. Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochem Biophys Res Commun 2007, 356:431-7. 10.1016/j.bbrc.2007.02.148, 17359935.
7. Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002, 59:150-4. 10.1016/S0090-4295(01)01484-4, 11796313.
8. Lourda M, Trougakos IP, Gonos ES. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein. J Int J Cancer 2007, 12:611-22.
9. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000, 157:393-399. 10.1016/S0002-9440(10)64552-X, 1850123, 10934144.
10. Miyake H, Gleave ME, Arakawa S, Kamidomi S, Hara I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potentials. J Urol 2002, 167:2003-2008.
11. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004, 64:1834-42. 10.1158/0008-5472.CAN-03-2664, 14996747.
12. Chung J, Kwak C, Jin RJ, Lee CH, Lee KH, Lee SE. Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett 2004, 203:155-61. 10.1016/j.canlet.2003.07.008, 14732223.
13. Miyake H, Eto H, Hara I, So A, Li D, Gleave ME. Synergistic antitumor activity by combined treatment with gmcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. J Urol 2004, 171:2477-81. 10.1097/01.ju.0000118382.89456.f7, 15126879.
14. Muramaki M, So A, Hayashi N, Sowery R, Miyake H, Fujisawa M, Gleave ME. Chemosensitization of gmcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int 2009, 103:384-90. 10.1111/j.1464-410X.2008.08098.x, 19007378.
15. Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res 2009, 105:77-92.
16. Zhang K, Dong C, Jiao X, et al. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Laboratory Investigation 2011, 1-13.
17. Fritz IB, Burdzy K, Setchell B, Blaschuk O. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. Biol Reprod 1983, 28:1173-1188. 10.1095/biolreprod28.5.1173, 6871313.
18. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002, 34:1430-1448. 10.1016/S1357-2725(02)00041-9, 12200037.
19. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, Reichrath J. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006, 13:12-19. 10.1038/sj.cdd.4401779, 16179938.
20. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005, 7:909-915. 10.1038/ncb1291, 16113678.
21. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003, 278:11590-11600. 10.1074/jbc.M209233200, 12551933.
22. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008, 102:389-97. 10.1111/j.1464-410X.2008.07618.x, 18336596.
23. So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005, 4:1837-49. 10.1158/1535-7163.MCT-05-0178, 16373699.
24. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004, 3:223-32.
25. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001, 3:360-7. 10.1038/sj.neo.7900174, 1505861, 11571636.
26. Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R. Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 2010, 10:1647-61. 10.1586/era.10.148, 20942635.
27. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, Matsubara F, Sawabu N. Expression of clusterin in human pancreatic cancer. Pancreas 2002, 25:234-8. 10.1097/00006676-200210000-00004, 12370533.